Suliqua, known as Soliqua 100/33 in the United States, is a prescription medication used in the management of type 2 diabetes. It is a combination injectable medicine that contains two active ingredients: insulin glargine and lixisenatide. Insulin glargine is a long-acting insulin that helps regulate blood sugar levels throughout the day, while lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist that enhances glucose-dependent insulin release, suppresses elevated glucagon secretion, and slows gastric emptying. Together, these components work synergistically to improve glycemic control in adults with type 2 diabetes. Suliqua is typically prescribed when treatment with both long-acting insulin and a GLP-1 receptor agonist is appropriate, and it is used alongside diet and exercise to improve blood sugar control.